HORA-RLBP1 has been developed for the treatment of retinal dystrophy caused by mutations in the RLBP1 gene

HORA-RLBP1 is delivered in the form of a sterile vector suspension injected directly into the subretinal space, where it allows rapid and robust transgene expression in the targeted retinal cells.

HORA-RLBP1 is designed as a gene replacement product, i.e., to provide the cells with a non-mutated copy of the human RLBP1 gene, thereby enabling expression of functional CRALBP and improving visual function, or at the very least significantly slowing retinal degeneration, in patients with RLBP1 mutations.


Horama does not own any office in Australia.

The company was warned that someone, claiming to be Christine Placet or Christen Placet, had contacted australian job seekers.

If you see a job offer matching this description, do not answer.

Horama has filed a complaint.